Research News | Oct. 29, 2014

Study Identifies Possible Method to Block Production of Antibodies Associated with Lupus

Lupus Foundation of America supported study demonstrates that blocking STAT5 reduces the production of CD154 by half.

Research News | Oct. 20, 2014

Intensive Follow-Up Recommended for People Diagnosed with Lupus During Childhood

Adolescent-onset lupus has worse prognosis and increased risk of lupus-related kidney disease and death.

General News | Sep. 30, 2014

Foundation Announces Pediatric Lupus Research Grantee & LIFELINE Grant Program™ Recipients

The Lupus Foundation of America announced four grants that will allow lupus investigators to continue critical lupus research. Another grant will be used to develop a groundbreaking diagnostic tool for children with lupus-related kidney inflammation, or lupus nephritis.

General News | Sep. 24, 2014

Foundation Welcomes NIH’s Accelerating Medicines Partnership in Lupus and RA Grantees

The Lupus Foundation of America congratulates and welcomes the first 11 new research groups that have been awarded grants as part of the Accelerating Medicines Partnership in Lupus and Rheumatoid Arthritis (AMP Lupus and RA) Network.

General News | Sep. 09, 2014

Leading Orgs Take to the Hill to Discuss Need to Accelerate New Medicines for Lupus & Other Diseases

Lupus Foundation of America and Rheumatology Research Foundation hold congressional briefing

Video | Aug. 07, 2014

Cardiovascular Disease Risk Factors and Events in the Pittsburgh Lupus Cohort Over 20 Years

Jennifer Mall, M.P.H. discusses her research project as part of her Gina Finzi Fellowship experience during the summer of 2014.

Research News | Aug. 01, 2014

Clinical Trial of Adult Stem Cells Takes Another Step Forward

Study funded by the Foundation's National Lupus Research Program secures NIH planning grant to develop a multi-center trial of mesenchymal stem cells.

Research News | Jul. 31, 2014

Mixed Results for Phase II Clinical Study of Atacicept in Lupus

Flare rates among participants receiving a low dose of the b-cell blocker did not meet primary endpoint but were lower for individuals receiving a higher dose.